
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cancer Epidemiology Biomarkers & Prevention, Vol 7, Issue 8 703-709, Copyright © 1998 by American Association for Cancer Research
ARTICLES |
R Pastorelli, M Guanci, A Cerri, E Negri, C La Vecchia, F Fumagalli, M Mezzetti, R Cappelli, T Panigalli, R Fanelli and L Airoldi
Department of Environmental Health Sciences, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy.
The benzo(a)pyrene (BaP) metabolite benzo(a)pyrenediolepoxide (BPDE) is strongly implicated as a causative agent of lung cancer. To assess the risk of exposure to BaP, we made a combined analysis of levels of BPDE adducts to hemoglobin (Hb), serum albumin (SA), and lymphocyte DNA in 44 patients with incident lung cancer, as a prototype of a population mainly exposed to tobacco-derived BaP. We also investigated whether genetic polymorphisms of cytochrome P450IA1 (CYPIA1), microsomal epoxide hydrolase (mEH), and glutathione S-transferase M1 (GSTM1), which are involved in BaP metabolism, can be determinants of adduct formation. BPDE-Hb, BPDE-SA, and BPDE-DNA adducts were quantified as BaP tetrols released from hydrolysis of macromolecules and measured by high-resolution gas chromatography-negative ion chemical ionization-mass spectrometry to achieve high specificity and sensitivity. Individuals with detectable Hb adducts were positive for SA adducts but not vice versa, suggesting that BPDE-Hb adducts are less informative indicators of BaP exposure. Using PCR methods on DNA, we characterized GSTM1 deletion, CYPIA1 MspI and exon 7 valine variants, and mEH polymorphisms at amino acid positions 113 (EH3) and 139 (EH4). Levels of BPDE adducts were no different among CYPIA1, mEH, and GSTM1 genotypes. However, individuals with measurable BPDE-SA adducts were CYPIA1 variant carriers more frequently (P = 0.03). There was a slightly higher percentage of DNA detectable adducts in subjects with CYPIA1 exon 7 valine polymorphism. When subjects were classified by both polymorphisms on the mEH gene, those with two slow alleles (EH3 homozygous mutated) and no fast alleles (EH4 homozygous wild type) had a lower frequency of BPDE-SA adducts and no DNA adducts (P = 0.06). These results are based on a small number of observations thus far, but this exploratory study suggests that CYPIA1 and mEH variants might have an impact on BPDE exposure markers such as BPDE-SA adducts. Chemical specificity in adduct measurements is important to identify the biomarkers that reflect BaP exposure more accurately.
This article has been cited by other articles:
![]() |
S-L Cheng, H-C Wang, C-J Yu, and P-C Yang Increased expression of placenta growth factor in COPD Thorax, June 1, 2008; 63(6): 500 - 506. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. De Roos, N. Rothman, M. Brown, D. A. Bell, G. S. Pittman, W. R. Shapiro, R. G. Selker, H. A. Fine, P. M. Black, and P. D. Inskip Variation in genes relevant to aromatic hydrocarbon metabolism and the risk of adult brain tumors. Neuro-oncol, April 1, 2006; 8(2): 145 - 155. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Culea, O. Cozar, and E. Culea PAHs in Cigarette Smoke by Gas Chromatography-Mass Spectrometry Indoor and Built Environment, June 1, 2005; 14(3-4): 283 - 292. [Abstract] [PDF] |
||||
![]() |
W.-Y. Huang, N. Chatterjee, S. Chanock, M. Dean, M. Yeager, R. E. Schoen, L.-F. Hou, S. I. Berndt, S. Yadavalli, C. C. Johnson, et al. Microsomal Epoxide Hydrolase Polymorphisms and Risk for Advanced Colorectal Adenoma Cancer Epidemiol. Biomarkers Prev., January 1, 2005; 14(1): 152 - 157. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Leng, Y. Dai, Y. Niu, Z. Pan, X. Li, J. Cheng, F. He, and Y. Zheng Effects of Genetic Polymorphisms of Metabolic Enzymes on Cytokinesis-Block Micronucleus in Peripheral Blood Lymphocyte among Coke-Oven Workers Cancer Epidemiol. Biomarkers Prev., October 1, 2004; 13(10): 1631 - 1639. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Lodovici, C. Luceri, F. Guglielmi, C. Bacci, V. Akpan, M. L. Fonnesu, V. Boddi, and P. Dolara Benzo(a)pyrene Diolepoxide (BPDE)-DNA Adduct Levels in Leukocytes of Smokers in Relation to Polymorphism of CYP1A1, GSTM1, GSTP1, GSTT1, and mEH Cancer Epidemiol. Biomarkers Prev., August 1, 2004; 13(8): 1342 - 1348. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Ahsan and A. G. Rundle Measures of genotype versus gene products: promise and pitfalls in cancer prevention Carcinogenesis, September 1, 2003; 24(9): 1429 - 1434. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. H. Phillips Smoking-related DNA and protein adducts in human tissues Carcinogenesis, December 1, 2002; 23(12): 1979 - 2004. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. G. Shields Tobacco Smoking, Harm Reduction, and Biomarkers J Natl Cancer Inst, October 2, 2002; 94(19): 1435 - 1444. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. F. Firozi, M. L. Bondy, A. A. Sahin, P. Chang, F. Lukmanji, E. S. Singletary, M. M. Hassan, and D. Li Aromatic DNA adducts and polymorphisms of CYP1A1, NAT2, and GSTM1 in breast cancer Carcinogenesis, February 1, 2002; 23(2): 301 - 306. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. W. Tiemersma, R. E. Omer, A. Bunschoten, P. van't Veer, F. J. Kok, M. O. Idris, A. M. Y. Kadaru, S. S. Fedail, and E. Kampman Role of Genetic Polymorphism of Glutathione-S-Transferase T1 and Microsomal Epoxide Hydrolase in Aflatoxin-associated Hepatocellular Carcinoma Cancer Epidemiol. Biomarkers Prev., July 1, 2001; 10(7): 785 - 791. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Sarmanova, K. Benesova, I. Gut, V. Nedelcheva-Kristensen, L. Tynkova, and P. Soucek Genetic polymorphisms of biotransformation enzymes in patients with Hodgkin's and non-Hodgkin's lymphomas Hum. Mol. Genet., June 1, 2001; 10(12): 1265 - 1273. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Zhou, S. W. Thurston, G. Liu, L. L. Xu, D. P. Miller, J. C. Wain, T. J. Lynch, L. Su, and D. C. Christiani The Interaction between Microsomal Epoxide Hydrolase Polymorphisms and Cumulative Cigarette Smoking in Different Histological Subtypes of Lung Cancer Cancer Epidemiol. Biomarkers Prev., May 1, 2001; 10(5): 461 - 466. [Abstract] [Full Text] |
||||
![]() |
A. J. SANDFORD, T. CHAGANI, T. D. WEIR, J. E. CONNETT, N. R. ANTHONISEN, and P. D. PARÉ Susceptibility Genes for Rapid Decline of Lung Function in the Lung Health Study Am. J. Respir. Crit. Care Med., February 1, 2001; 163(2): 469 - 473. [Abstract] [Full Text] |
||||
![]() |
A. Rundle, D. Tang, J. Zhou, S. Cho, and F. Perera The Association between Glutathione S-Transferase M1 Genotype and Polycyclic Aromatic Hydrocarbon-DNA Adducts in Breast Tissue Cancer Epidemiol. Biomarkers Prev., October 1, 2000; 9(10): 1079 - 1085. [Abstract] [Full Text] |
||||
![]() |
C. C. Özbal, P. L. Skipper, M. C. Yu, S. J. London, R. R. Dasari, and S. R. Tannenbaum Quantification of (7S,8R)-Dihydroxy-(9R,10S)-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene Adducts in Human Serum Albumin by Laser-induced Fluorescence: Implications for the in Vivo Metabolism of Benzo[a]pyrene Cancer Epidemiol. Biomarkers Prev., July 1, 2000; 9(7): 733 - 739. [Abstract] [Full Text] |
||||
![]() |
G. Scherer, S. Frank, K. Riedel, I. Meger-Kossien, and T. Renner Biomonitoring of Exposure to Polycyclic Aromatic Hydrocarbons of Nonoccupationally Exposed Persons Cancer Epidemiol. Biomarkers Prev., April 1, 2000; 9(4): 373 - 380. [Abstract] [Full Text] |
||||
![]() |
H. Bartsch, U. Nair, A. Risch, M. Rojas, H. Wikman, and K. Alexandrov Genetic Polymorphism of CYP Genes, Alone or in Combination, as a Risk Modifier of Tobacco-related Cancers Cancer Epidemiol. Biomarkers Prev., January 1, 2000; 9(1): 3 - 28. [Abstract] [Full Text] |
||||
![]() |
M. Rojas, I. Cascorbi, K. Alexandrov, E. Kriek, G. Auburtin, L. Mayer, A. Kopp-Schneider, I. Roots, and H. Bartsch Modulation of benzo[a]pyrene diolepoxide-DNA adduct levels in human white blood cells by CYP1A1, GSTM1 and GSTT1 polymorphism Carcinogenesis, January 1, 2000; 21(1): 35 - 41. [Abstract] [Full Text] [PDF] |
||||
![]() |
D.H. Phillips and M. Castegnaro Standardization and validation of DNA adduct postlabelling methods: report of interlaboratory trials and production of recommended protocols Mutagenesis, May 1, 1999; 14(3): 301 - 315. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |